Stockscreener 앱 받기
12.51
2.38%
-0.305
시장 영업 전:
13.01
0.50
+4.00%
Pharming Group Nv Adr 주식(PHAR)의 최신 뉴스
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Pharming Group N.V. Investigated by the Portnoy Law Firm - GlobeNewswire
Pharming (NASDAQ: PHAR) updates 20-F with corrected CEO/CFO certifications - Stock Titan
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 33.9% in March - MarketBeat
Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright - defenseworld.net
HC Wainwright Estimates Pharming Group Q3 Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest - MarketBeat
HC Wainwright Predicts Pharming Group Q1 Earnings - MarketBeat
A2QLQY Stock Price and Chart — LS:A2QLQY - TradingView
Wainwright reiterates Pharming stock Buy rating on commercial growth - Investing.com
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - Finviz
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Drop in Short Interest - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V.PHAR - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - GlobeNewswire Inc.
FY2025 EPS Estimates for Pharming Group Increased by Analyst - Defense World
Pharming shares surge as 2026 guidance tops analyst expectations - Investing.com
Pharming Group stock tumbles after FDA issues Complete Response Letter - Investing.com
1.27%
1.43%
자본화:
|
볼륨(24시간):